Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

Atea Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ:AVIR opened at $3.03 on Friday. The firm has a market capitalization of $255.92 million, a PE ratio of -1.46 and a beta of 0.19. Atea Pharmaceuticals has a 1-year low of $2.75 and a 1-year high of $4.60. The business’s 50 day moving average is $3.19 and its 200-day moving average is $3.37.

Insider Buying and Selling

In related news, Director Franklin M. Berger sold 359,606 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the transaction, the director now owns 451,897 shares in the company, valued at $1,287,906.45. This trade represents a 44.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 17.80% of the stock is owned by corporate insiders.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.